Hudson Tompkins

Hudson Tompkins serves as a key procurement lead within the Defense Health Agency, responsible for managing high-priority acquisitions aligned with the agency’s mission to ensure operational medical readiness across the global Department of Defense footprint. He specializes in pharmaceutical manufacturing and supply chain contracts, overseeing the acquisition of critical medications, sterile injectables, and advanced pharmaceutical preparations that support military treatment facilities and deployed forces. His work directly enables clinical continuity, emergency response capacity, and compliance with DoD pharmaceutical standards, making him a central figure in sustaining the health infrastructure for service members, retirees, and their families. Tompkins maintains consistent contracting relationships with a select group of specialized vendors, including DEPENDABLE ON-SITE SCAN & SHRED, INC., HANITH BIOSCIENCE, LLC, LIVION TECHNOLOGY, LLC, I-2-I SOLUTIONS, INC., and DRAEGER INC. These partnerships reflect a focus on niche capabilities in pharmaceutical compounding, biotechnology development, medical device integration, and secure logistics. His contracting approach emphasizes technical precision, regulatory compliance, and supply chain resilience, favoring vendors with proven expertise in FDA-regulated manufacturing and defense-grade quality assurance protocols. Tompkins does not utilize socioeconomic set-asides, with 100% of his awards issued under full and open competition. This reflects a strategic preference for technical merit and mission-critical capability over socioeconomic targeting, prioritizing rapid acquisition cycles and proven performance in high-stakes pharmaceutical environments. While small business participation is not formally incentivized in his portfolio, vendor selection remains rigorous and performance-driven. His procurement activity is exclusively concentrated in NAICS 325412 — Pharmaceutical Preparation Manufacturing — underscoring deep expertise in the procurement of sterile, injectable, and oral solid-dose medications, as well as related manufacturing and packaging systems. He operates at the intersection of clinical demand, defense logistics, and federal pharmaceutical regulation, ensuring that the DHA’s medical supply chain remains secure, scalable, and mission-ready.